Prne
September 30th, 2009
PARIS -
- New Generation Emergency Contraception now Commercially Available in France, Germany and the United Kingdom, in Anticipation of Upcoming Launch Throughout European Union
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
ellaOne(R) is the first representative of a new therapeutic class, selective progesterone receptor modulators, and is the first molecule to have been specifically designed and developed for use as an oral emergency contraceptive. Clinical trials performed on more than 4000 women have shown that a single dose of ellaOne significantly reduces the number of pregnancies versus the number of expected pregnancies in absence of emergency contraception. ellaOne is different from currently used levonorgestrel-based emergency contraceptives, in that it maintains efficacy for 5 days after unprotected intercourse while its safety and tolerability profile has been demonstrated to be comparable to that of levonorgestrel.
“Our company is committed to advancing the discovery and development of new medicines tackling unmet needs in the field of reproductive health,” said Erin Gainer, CEO of HRA Pharma. “The European launch of ellaOne is the result of more than 10 years of research and development and represents an important milestone, as it is the first licensed product to have been specifically designed and developed for use as an oral emergency contraceptive.”
Since pioneering the launch of levonorgestrel for emergency contraception in 1999, HRA Pharma has been a leader in emergency contraception, providing solutions to unmet needs for millions of women in over 50 countries. The European launch of ellaOne is the first step in the international commercialisation of this product. The company plans to file for marketing approvals in countries worldwide under the trademarks ellaOne and ella, and continues to develop innovative projects in the field of reproductive health.
About HRA Pharma
HRA Pharma is an emerging, privately-held European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide. The company targets therapeutic gaps in the areas of reproductive health and endocrinology, and uses innovative marketing solutions and socially-conscious programs, such as contraception education in developing countries, to promote healthy management of drugs and diseases. A pioneer in emergency contraception, its product NorLevo was the first emergency contraceptive based on one type of progesterone to be approved for sale by health authorities. Headquartered in Paris, France and with subsidiaries in Germany, Italy and the United Kingdom HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe. Visit www.hrapharma.com for more information.
Source: HRA Pharma
Media Contact: Julian Barlow, Barlow Frith Communications Ltd for HRA Pharma, +44-(0)1296-468540, julian at barlowcomms.co.uk
Filed under Business, Health, Health Care / Hospitals, Multicultural, New Products / Services, Pharmaceuticals, Women Related | Tags: France, HRA Pharma, Paris | Comment Below
Related Press Releases CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech ConvergenceOctober 6th, 2009 MAARSSEN, Netherlands -
CPhI Worldwide and connected events - the global pharma ingredients and services community's largest annual meeting - returns to Madrid on 12 - 15 October for its 20th staging. The co-located ICSE contract services and P-MEC equipment and technology events are joined for 2009 under the Where Pharma Meets banner by the new, biotech-focused BioPh. Astellas Pharma Europe Announces Winners of the Changing Tomorrow 2009 AwardsSeptember 22nd, 2009 STAINES, England - Astellas Pharma Europe Ltd., the European subsidiary of Tokyo-based Astellas Pharma Inc., one of the world's top 20 pharmaceutical companies, has today announced the launch of the Astellas Changing Tomorrow Charity Awards. The charity award funding programme is designed to award organisations that help citizens of all communities realise their full potential and enhance their quality of life - both today and in the future. Dutch Top Institute Pharma Attracts International InterestSeptember 9th, 2009 LEIDEN, The Netherlands - The Danish Council for Strategic Research is visiting the Dutch Top Institute Pharma (TI Pharma) on Thursday, September 10. The purpose of their visit is to learn about the unique Dutch approach on public-private cooperation and the concrete results that are being booked by this institute. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotratm In RASeptember 1st, 2009 BASEL and REINACH, Switzerland -
- CAPRA-2-Data Will be Used to File for US Marketing Approval
Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM). The CAPRA-2 study (Circadian Administration of Prednisone in Rheumatoid Arthritis-2) was a 12-week, multicentre, double-blind phase III trial evaluating the safety and efficacy of Lodotra(TM) for the treatment of rheumatoid arthritis ("RA"), a chronic, progressive and disabling autoimmune disorder. Sao Paulo Hosts Second CPhI and P-MEC South America Pharma EventsAugust 5th, 2009 MAARSSEN, Netherlands -
Against the background of continuing strong market growth, Sao Paulo will host the second CPhI South America and P-MEC South America pharma ingredients and production technology events on Wednesday 26 - Friday 28 August. Staged by UBM International Media, the debut events in Rio last August welcomed over 180 exhibitors and nearly 4,500 attendees. Paris Dates for CPhI Worldwide 2010June 14th, 2009 MAARSSEN, Netherlands - CPhI Worldwide returns to Paris for 2010 when, with ICSE, PMEC and BioPh, the world's leading pharma services industry event will be staged at Paris-Nord Villepinte on Tuesday 5 - Thursday 7 October. This is a week earlier than the 2009 event in Madrid, but close to the dates of the last staging in Paris, in 2006. HRA Pharma Granted European Marketing Authorization for ellaOne(R)May 25th, 2009 PARIS - Next Generation Emergency Contraceptive Will First be Launched in UK, Germany and France as Company Expands International Operations
HRA Pharma (www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate), its next generation emergency contraceptive, has been granted marketing authorization by the European Commission. The unanimous decision by all member states enables HRA Pharma to begin marketing ellaOne throughout the European Union, making it the only approved product to have been specifically designed and developed for use as an emergency contraceptive. Teikoku Pharma USA Acquires Travanti Pharma Inc.May 7th, 2009 SAN JOSE, California - Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body. The Company has developed a proprietary Wearable Electronic Disposable Drug delivery technology (WEDD(R)) Platform. Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry EyeApril 14th, 2009 EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome. BioCis Pharma Starts Phase IIa Trial in PsoriasisMarch 11th, 2009 TURKU, Finland - BioCis Pharma Ltd., a privately-held drug development company with its
headquarters in Turku, Finland, announced that it has begun a new Phase IIa
clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical
drug for dermatology. The double-blind, vehicle-controlled study is designed
to evaluate the tolerability, pharmacokinetics, and efficacy of the topical
product in a total of 18 subjects with mild to moderate plaque psoriasis.
Related News Dainippon Sumitomo Pharma of Japan acquiring US drug maker Sepracor for $2.6 billionSeptember 3rd, 2009 Dainippon of Japan acquires US drug maker SepracorTOKYO — Japanese drug company Dainippon Sumitomo Pharma Co. is acquiring U.S. IndiaMART launches mega sourcing portalOctober 6th, 2009 NEW DELHI - IndiaMART.com has announced the launch of its mega sourcing portal, http://sourcing.indiamart.com, which will offer a deep and wide treasure trove of product-related content for prospective buyers and suppliers. Sourcing.indiamart.com will have eight categories - agro, apparel, auto, building materials, electrical, engineering, handicraft and pharma. Emami to demerge realty, Zandu Pharma unitJune 19th, 2009 MUMBAI - The boards of Emami and Zandu Pharma have approved hiving off Emami's realty business into a separate firm, and merging Zandu's consumer goods (FMCG) unit with Emami, the companies said Friday. "The realty business of Emami will be now a separate company, Emami Infrastructure Ltd," Emami said in regulatory statement. Four Gujarat pharma units found stashing used syringesMarch 6th, 2009 AHMEDABAD - In what could be termed an eye opener for other pollution control bodies across India, the Gujarat Pollution Control Board (GPCB) has so far found four pharmaceutical units near here storing used syringes and needles in their warehouses. Board officials raided the factories Thursday afternoon after being told by the Ahmedabad Municipal Corporation (AMC) about the possibility of the four pharma units in Naroda, Narol and Isanpur storing used syringes and needles. GVK Biosciences announces appointment of Gerhard N. Mayr to its Board of DirectorsAugust 4th, 2009 HYDERABAD - GVK Biosciences (GVK BIO) today announced the appointment of Gerhard N. Mayr to its Board of Directors. Fiat India launches luxury sedan in IndiaJanuary 15th, 2009 NEW DELHI - Auto manufacturer Fiat India Friday launched its luxury sedan Fiat Linea in India. The car will be available in both diesel and petrol versions. Indian firms' investments in Europe may drop: FICCIJune 21st, 2009 NEW DELHI - Indian corporates, which invested 2.4 billion euros ($3.35 billion) in European Union (EU) last year, are unlikely to pump in as much money in 2009 as they think it may take upto one year for Europe to recover from the slowdown, says a survey. "Indian investments in the EU during the current year may not reach the 2008 mark of 2.4 billion euros," the survey conducted by the Federation of Indian Chambers of Commerce and Industry (FICCI) said. Maxygen CEO and CFO to leave Wednesday as part of expanded partnership with Astellas PharmaSeptember 30th, 2009 Maxygen says CEO and CFO will leave Sept. 30NEW YORK — Maxygen Inc. Sea Launch Co. files for Chapter 11 reorganizationJune 24th, 2009 Sea Launch Co. files for Chapter 11 reorganizationLONG BEACH, Calif. Rocket launches may need regulation to prevent ozone destructionApril 1st, 2009 WASHINGTON - Rocket launches in future may require more stringent regulation to minimise damage to the ozone layer of the Earth's atmosphere, according to a new study. Today, just a handful of NASA space shuttle launches release more ozone-depleting substances in the stratosphere than the entire annual use of CFC-based medical inhalers used to treat asthma and other diseases in the US, said Darin Toohey, professor of Colorado University at Boulder (CUB) atmospheric and oceanic sciences department.
|
|
